Effects of ivabradine on cardiovascular events in patients with moderate-to-severe chronic heart failure and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled international multicentre study.

Trial Profile

Effects of ivabradine on cardiovascular events in patients with moderate-to-severe chronic heart failure and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled international multicentre study.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Ivabradine (Primary)
  • Indications Chronic heart failure; Left ventricular dysfunction
  • Focus Registrational; Therapeutic Use
  • Acronyms SHIFT
  • Sponsors IRIS; Servier
  • Most Recent Events

    • 10 Jan 2017 According to a Servier Canada media release dated 10 Jan 2017, Health Canada has issued a Notice of Compliance for LANCORA (ivabradine) in patients suffering from chronic heart failure. This approval is based on a complete clinical development program, including the SHIFT trial.
    • 16 Nov 2016 Results (n=3741) presented at the 89th Annual Scientific Sessions of the American Heart Association.
    • 16 Nov 2016 Results (n=5038) of PRO-SHIFT substudy assessing the impact of recurrent cardiovascular (CV) hospitalizations and treatment on patient quality of life, presented at the 89th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top